Literature DB >> 15122249

Dendritic cell immunotherapy: mapping the way.

Carl G Figdor1, I Jolanda M de Vries, W Joost Lesterhuis, Cornelis J M Melief.   

Abstract

Dendritic cells (DCs) are the professional antigen-presenting cells of the immune system, with the potential to either stimulate or inhibit immune responses. Exploiting the immune-regulatory capacities of dendritic cells holds great promise for the treatment of cancer, autoimmune diseases and the prevention of transplant rejection. Although early clinical trials indicate that DC vaccines can induce immune responses in some cancer patients, careful study design and use of standardized clinical and immunological criteria are needed.

Entities:  

Mesh：

Substances：

Year:  2004        PMID： 15122249     DOI： 10.1038/nm1039

Source DB:  PubMed          Journal:  Nat Med        ISSN： 1078-8956            Impact factor:   53.440


  268 in total

Review 1.  Functionalized carbon nanotubes for potential medicinal applications.

Authors:  Yi Zhang; Yuhong Bai; Bing Yan
Journal:  Drug Discov Today       Date:  2010-05-06       Impact factor: 7.851

2.  A phase I pilot trial of MUC1-peptide-pulsed dendritic cells in the treatment of advanced pancreatic cancer.

Authors:  Yefei Rong; Xia Qin; Dayong Jin; Wenhui Lou; Lili Wu; Dansong Wang; Wenchuan Wu; Xiaolin Ni; Zhengfa Mao; Tiantao Kuang; Ying Qin Zang; Xinyu Qin
Journal:  Clin Exp Med       Date:  2011-09-20       Impact factor: 3.984

3.  Specifically activated dendritic cells--cell-based vaccine against lymphosarcoma exhibiting multiple drug resistance phenotype.

Authors:  N L Mironova; E E Panzinskyi; N A Popova; V P Nikolin; M A Zenkova; V V Vlasov
Journal:  Dokl Biochem Biophys       Date:  2009 Sep-Oct       Impact factor: 0.788

Review 4.  Immunization delivered by lentiviral vectors for cancer and infectious diseases.

Authors:  Biliang Hu; April Tai; Pin Wang
Journal:  Immunol Rev       Date:  2011-01       Impact factor: 12.988

5.  Synergistical toll-like receptors activated dendritic cells induce antitumor effects against carcinoembryonic antigen-expressing colon cancer.

Authors:  Xinqiang Hong; Tiangen Dong; Jianwei Hu; Tuo Yi; Wenxiang Li; Zhen Zhang; Shengli Lin; Weixin Niu
Journal:  Int J Colorectal Dis       Date:  2012-07-10       Impact factor: 2.571

6.  Targeting the intratumoral dendritic cells by the oncolytic adenoviral vaccine expressing RANTES elicits potent antitumor immunity.

Authors:  Natalia Lapteva; Melissa Aldrich; David Weksberg; Lisa Rollins; Tatiana Goltsova; Si-Yi Chen; Xue F Huang
Journal:  J Immunother       Date:  2009 Feb-Mar       Impact factor: 4.456

Review 7.  Immunotherapy and immunoescape in colorectal cancer.

Authors:  Guillermo Mazzolini; Oihana Murillo; Catalina Atorrasagasti; Juan Dubrot; Iñigo Tirapu; Miguel Rizzo; Ainhoa Arina; Carlos Alfaro; Arantza Azpilicueta; Carmen Berasain; José L Perez-Gracia; Alvaro Gonzalez; Ignacio Melero
Journal:  World J Gastroenterol       Date:  2007-11-28       Impact factor: 5.742

Review 8.  Prospective of colon cancer treatments and scope for combinatorial approach to enhanced cancer cell apoptosis.

Authors:  Jayshree Mishra; Joseph Drummond; Sohel H Quazi; Satya Sridhar Karanki; J J Shaw; Ben Chen; Narendra Kumar
Journal:  Crit Rev Oncol Hematol       Date:  2012-10-23       Impact factor: 6.312

9.  mRNA-transfected dendritic cell vaccine in combination with metronomic cyclophosphamide as treatment for patients with advanced malignant melanoma.

Authors:  Troels Holz Borch; Lotte Engell-Noerregaard; Trine Zeeberg Iversen; Eva Ellebaek; Özcan Met; Morten Hansen; Mads Hald Andersen; Per Thor Straten; Inge Marie Svane
Journal:  Oncoimmunology       Date:  2016-07-08       Impact factor: 8.110

10.  Developing effective tumor vaccines: basis, challenges and perspectives.

Authors:  Qingwen Xu; Weifeng Chen
Journal:  Front Med China       Date:  2007-02-01
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.